FDA 2023 Q1 potential signals include Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) - Weight increased as a potential signal.
AERion Analytics DiscoverAE analysis includes 293 reports with primary suspect drug BICTEGRAVIR;EMTRICITABINE;TENOFOVIR and drug-AE disproportionality analysis shows the above-listed statistics. The PRR is above 2 at all ATC levels and against all reports submitted to the FAERS.
Comments